<DOC>
	<DOCNO>NCT00057759</DOCNO>
	<brief_summary>RATIONALE : Sildenafil may effective help patient undergone treatment prostate cancer erection sexual activity may improve sexual satisfaction quality life . PURPOSE : Randomized clinical trial study effectiveness sildenafil treat erectile dysfunction patient undergone radiation therapy hormone therapy prostate cancer clinical trial RTOG-9910 .</brief_summary>
	<brief_title>Sildenafil Treating Erectile Dysfunction Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect sildenafil v placebo erectile dysfunction patient prostate cancer treat radiotherapy antiandrogens RTOG-9910 . - Compare overall sexual function satisfaction patient treat regimen . - Compare sexual satisfaction partner patient treat regimen . - Compare patient partner marital adjustment treatment regimen . - Determine factor may predict response sildenafil , include age , pretreatment sexual function , tobacco use , comorbidities patient . OUTLINE : This randomize , placebo-controlled , multicenter study . Patients stratify accord prior use sildenafil treatment RTOG-9910 level response ( No v yes [ unsatisfactory ] v yes [ satisfactory ] ) , International Index Erectile Function ( IIEF ) Question # 1 score ( 0-1 v 2-3 ) , RTOG-9910 treatment arm ( I vs II ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral sildenafil 1 hour prior desire sexual intercourse . - Arm II : Patients receive oral placebo 1 hour prior desire sexual intercourse . Treatment arm continue 12 week . Patients cross treatment arm 12 week . Quality life , include sexual function , marital adjustment , partner 's satisfaction , assessed baseline , 12 25 week , 1 year . Patients follow 1 year . PROJECTED ACCRUAL : A total 332 patient ( 166 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Prior treatment RTOG9910 intermediate relapserisk stage II III prostate cancer determine follow combination factor : T1b4 , Gleason score 26 , prostatespecific antigen ( PSA ) great 10 ng/mL great 100 ng/mL T1b4 , Gleason score 7 , PSA le 20 ng/mL T1b1c , Gleason score 810 , PSA le 20 ng/mL Radiotherapy complete within past 6 month 5 year Pretreatment ( enrollment study ) erectile dysfunction measure International Index Erectile Function Question # 1 Erectile dysfunction start prostate cancer therapy allow Patients without partner without partner willing participate allow PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular No myocardial infarction within past year Other No invasive cancer within past 5 year except localize basal cell squamous cell skin cancer ( stage 0II ) No anatomical genital abnormality concurrent condition would prohibit sexual intercourse preclude study participation No major medical psychiatric illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy More 6 month since prior androgen suppression ( e.g. , leuprolide goserelin ) , antiandrogen ( e.g. , bicalutamide , flutamide , nilutamide ) , estrogenic ( e.g. , diethylstilbestrol ) agent Radiotherapy See Disease Characteristics Surgery No prior penile implant No prior bilateral orchiectomy Other No concurrent sildenafil No concurrent participation another medical research study treat prostate cancer No concurrent organic nitrate requirement nitrate ( e.g. , nitroglycerin need ) No concurrent ketoconazole , itraconazole , erythromycin No concurrent use mechanical ( vacuum ) device intracorporeal , intraurethral , topical , oral agent erectile dysfunction</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>sexual dysfunction</keyword>
	<keyword>sexuality reproductive issue</keyword>
	<keyword>radiation toxicity</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>psychosocial effect cancer treatment</keyword>
</DOC>